8-K: Century Therapeutics Reports Positive Clinical Data and Extends Cash Runway into Second Half of 2026

Century Therapeutics announced positive interim results from its Phase 1 trials of CNTY-101, expanded its autoimmune disease focus, and extended its cash runway into the second half of 2026 through organizational efficiencies.

Summary

• Century Therapeutics reported its third quarter 2024 financial results and provided business updates, including the expansion of the Phase 1 CALiPSO-1 trial of CNTY-101 to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy.
• The company observed an 83% overall response rate at CNTY-101 Dose Level 3B with a favorable safety profile in patients with relapsed or refractory B-cell lymphomas in the Phase 1 ELiPSE-1 study.
• CNTY-101 demonstrated persistence upon repeated cell dosing at Dose Level 3B, which is consistent with the anticipated protective activity of Century's proprietary Allo-Evasion technology.
• Century ended the third quarter of 2024 with $244.7 million in cash, cash equivalents, and investments, and organizational efficiencies have extended the expected cash runway into the second half of 2026.
• The company is conducting a strategic review of its pre-clinical pipeline and expects to announce the outcome in the first quarter of 2025.
• Century has refined its organizational structure to enhance efficiencies and program alignment, which included the elimination of some overlapping technical and research capabilities.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, an extended cash runway, and strategic pipeline advancements. The company is making good progress in its clinical trials and has a clear path forward. However, the company is still in the early stages of development and faces significant risks.

Positives

• The expansion of the CALiPSO-1 trial to include additional autoimmune diseases broadens the potential application of CNTY-101.
• The 83% overall response rate in the ELiPSE-1 study is a strong indicator of CNTY-101's efficacy in treating B-cell lymphomas.
• The persistence of CNTY-101 upon repeated dosing suggests the Allo-Evasion technology is working as intended.
• The extended cash runway provides financial stability and allows the company to focus on clinical development.
• The strategic review of the pre-clinical pipeline could lead to more focused and efficient research efforts.
• The company has a strong cash position of $244.7 million as of September 30, 2024.
• The company has observed a dose-dependent increase in CNTY-101 exposure.
• The company has observed efficient B-cell depletion in all participants treated with CNTY-101 who had measurable circulating B cells at baseline.
• The company has observed a reduction of class-switched phenotypes in re-emergent B cells, which has been associated with SLE responses after CD19 cell therapy treatment.

Negatives

• Net cash used in operations increased to $85.9 million for the nine months ended September 30, 2024, compared to $62.1 million for the same period in 2023.
• The company experienced a net loss of $31.2 million for the three months ended September 30, 2024.
• The company has eliminated some overlapping technical and research capabilities, which may have a short-term impact on operations.
• The company has a history of net losses and negative cash flow from operations.

Risks

• The company's ability to successfully advance product candidates through clinical trials is subject to inherent risks and uncertainties.
• The company is dependent on the success of its lead product candidate, CNTY-101.
• The results of preliminary data and earlier-stage clinical trials may not be predictive of final results.
• The company relies on key collaborative relationships for manufacturing and development.
• The company's ability to obtain regulatory approvals is not guaranteed.
• Geopolitical issues, banking instability, and inflation could impact the company's business and operations.
• The company's ability to commercialize product candidates and develop sales and marketing capabilities is uncertain.
• The company's ability to recruit and maintain key members of management is critical to its success.
• The company's ability to maintain and enforce adequate intellectual property protection is essential.

Future Outlook

The company expects its cash, cash equivalents, and investments to support operations into the second half of 2026 and anticipates providing updated clinical data from the ELiPSE-1 study by mid-2025. The company also expects to conclude its strategic review of the pre-clinical pipeline in the first quarter of 2025.

Management Comments

• Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, stated that the expansion of the autoimmune disease focus will give greater insight into the potential of CNTY-101.
• Brent Pfeiffenberger also noted that the updated interim data from the ELiPSE-1 trial shows increased overall response rates at higher doses and observations of deepening responses with additional cycles.
• Management highlighted the industry-first presentation of iPSC-derived CD4+ and CD8+ CAR T cells at the upcoming American Society of Hematology Annual Meeting.

Industry Context

This announcement is significant in the context of the broader cell therapy industry, as it highlights the potential of iPSC-derived cell therapies to overcome the limitations of first-generation cell therapies. The expansion into autoimmune diseases and the positive clinical data for CNTY-101 position Century Therapeutics as a key player in the next generation of cell therapies.

Comparison to Industry Standards

• The 83% overall response rate at Dose Level 3B in the ELiPSE-1 study is highly competitive compared to other cell therapies in relapsed/refractory B-cell lymphomas, such as autologous CAR T-cell therapies which have shown approximately 40% curative rates.
• The use of Allo-Evasion technology to enable repeat dosing is a significant advancement over traditional allogeneic cell therapies, which often face challenges with host rejection.
• The company's focus on iPSC-derived cell therapies provides a potential advantage in terms of scalability, consistency, and cost of goods compared to donor-derived or autologous cell products.
• The expansion of the CALiPSO-1 trial to include multiple autoimmune indications is a strategic move to address a significant unmet need in the market, similar to other companies exploring cell therapies for autoimmune diseases, such as those targeting lupus and other inflammatory conditions.
• The company's cash runway into the second half of 2026 is a positive sign of financial stability, which is crucial for long-term clinical development, and is comparable to other well-funded biotech companies in the cell therapy space.

Management Changes

Stakeholder Impact

• Shareholders will likely view the positive clinical data and extended cash runway favorably.
• Employees may be impacted by the organizational restructuring, but the company is focused on enhancing efficiencies.
• Patients with autoimmune diseases and B-cell lymphomas may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities as the company progresses its clinical programs.

Next Steps

• The company will continue to enroll patients in the CALiPSO-1 trial across multiple autoimmune indications.
• The company will proceed with dose escalation to DL4B in the ELiPSE-1 study.
• The company expects to provide updated clinical data from the ELiPSE-1 study by mid-2025.
• The company will conclude its strategic review of the pre-clinical pipeline in the first quarter of 2025.
• The company will present pre-clinical data at the 66th American Society of Hematology Annual Meeting.

Key Dates

Keywords

iPSC, cell therapy, CNTY-101, Allo-Evasion, autoimmune disease, B-cell lymphoma, clinical trial, immunotherapy, NK cells, CAR T cells